CN102458453A - 用于治疗精神分裂症和双相型障碍的组织激肽释放酶 - Google Patents

用于治疗精神分裂症和双相型障碍的组织激肽释放酶 Download PDF

Info

Publication number
CN102458453A
CN102458453A CN2010800272716A CN201080027271A CN102458453A CN 102458453 A CN102458453 A CN 102458453A CN 2010800272716 A CN2010800272716 A CN 2010800272716A CN 201080027271 A CN201080027271 A CN 201080027271A CN 102458453 A CN102458453 A CN 102458453A
Authority
CN
China
Prior art keywords
schizophrenia
per day
variant
klk1
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800272716A
Other languages
English (en)
Chinese (zh)
Inventor
M·威廉姆斯
M·查尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanomune Inc
Original Assignee
Sanomune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanomune Inc filed Critical Sanomune Inc
Publication of CN102458453A publication Critical patent/CN102458453A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CN2010800272716A 2009-04-21 2010-04-21 用于治疗精神分裂症和双相型障碍的组织激肽释放酶 Pending CN102458453A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17118909P 2009-04-21 2009-04-21
US61/171,189 2009-04-21
PCT/CA2010/000561 WO2010121358A1 (en) 2009-04-21 2010-04-21 Tissue kallikrein for the treatment of schizophrenia and bipolar disorder

Publications (1)

Publication Number Publication Date
CN102458453A true CN102458453A (zh) 2012-05-16

Family

ID=43010629

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800272716A Pending CN102458453A (zh) 2009-04-21 2010-04-21 用于治疗精神分裂症和双相型障碍的组织激肽释放酶

Country Status (6)

Country Link
US (1) US20120201804A1 (https=)
EP (1) EP2421553A4 (https=)
JP (1) JP2012524112A (https=)
CN (1) CN102458453A (https=)
CA (1) CA2759481A1 (https=)
WO (1) WO2010121358A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182978A4 (en) 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en) 2012-06-04 2013-12-05 Matthew Charles Human tissue kallikrein 1 glycosylation isoforms
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN109091667B (zh) * 2018-09-18 2020-05-05 广东天普生化医药股份有限公司 人尿激肽原酶在制备治疗偏头痛药物中的用途及其组合物
CN116549619A (zh) * 2022-01-28 2023-08-08 江苏众红生物工程创药研究院有限公司 激肽原酶及其衍生物在治疗vci、psci或csvd中的应用
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用
CN116549599A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 激肽及其衍生物在治疗vci、psci或csvd中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182978A4 (en) * 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
WO2010009557A1 (en) * 2008-07-25 2010-01-28 Sanomune Inc. Tissue kallikrein for the treatment of parkinson's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EUKARYOTA等: "AF277050.1", 《GENEBANK》 *
EUKARYOTA等: "AY290706.1", 《GENEBANK》 *
YAN XIA等: "《Lithium Protection of Phencyclidine-Induced Neurotoxicity in Developing Brain:The Role of Phosphatidylinositol-3 Kinase/Akt and Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways》", 《THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》 *
YU-YU YAO等: "《Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3β pathway》", 《CARDIOVASCULAR RESEARCH》 *

Also Published As

Publication number Publication date
JP2012524112A (ja) 2012-10-11
EP2421553A1 (en) 2012-02-29
CA2759481A1 (en) 2010-10-28
WO2010121358A1 (en) 2010-10-28
US20120201804A1 (en) 2012-08-09
EP2421553A4 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
CN102458453A (zh) 用于治疗精神分裂症和双相型障碍的组织激肽释放酶
Gao et al. Damage mechanism and therapy progress of the blood-brain barrier after ischemic stroke
Oudega Molecular and cellular mechanisms underlying the role of blood vessels in spinal cord injury and repair
Misiura et al. Proline‐containing peptides—New insight and implications: A Review
AU2008335490B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US11572396B2 (en) Therapeutic use of bone morphogenetic proteins
JP2010533657A (ja) アミロイドタンパク質に関係する疾患を治療するための組織カリクレイン
EP2440231B1 (en) Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
US20100056604A1 (en) Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv
KR20030096227A (ko) 신경 및 신경정신 질환의 치료방법
CA3042808A1 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
Lebrun-Julien et al. Molecular and cell-based approaches for neuroprotection in glaucoma
Lu et al. NAMPT inhibition reduces macrophage inflammation through the NAD+/PARP1 pathway to attenuate liver ischemia–reperfusion injury
CN110194787A (zh) 靶向抑制Wnt/β-catenin信号活性的多肽及其用途
Gong et al. Research developments in the neurovascular unit and the blood‑brain barrier
Yaguchi et al. Presence and physiologic function of the renin–angiotensin system in mouse lacrimal gland
US20110150781A1 (en) Tissue kallikrein for the treatment of parkinson's disease
BR112016019868B1 (pt) Uso da proteína de fusão tatk-cdkl5, formulação farmacêutica e seus usos
Montiel et al. Modulation of the autophagy‐lysosomal pathway and endoplasmic reticulum stress by ketone bodies in experimental models of stroke
ES2369760T3 (es) Péptido bloqueante para la secreción de células inflamatorias.
Nury et al. Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting
Yang et al. Unlocking the potential of the ACE2/Ang‐(1–7)/Mas Axis in liver diseases: From molecular mechanisms to translational applications
TW200305447A (en) Methods and compositions for treating respiratory pathologies
EP4601630A1 (en) Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity
Gershon et al. The ideal anxiolytic

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120516